Premium
Guideline of guidelines: non‐muscle‐invasive bladder cancer
Author(s) -
Woldu Solomon L.,
Bagrodia Aditya,
Lotan Yair
Publication year - 2017
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13760
Subject(s) - bladder cancer , medicine , guideline , nice , excellence , disease , cystoscopy , cancer , family medicine , intensive care medicine , pathology , urinary system , computer science , political science , law , programming language
Non‐muscle‐invasive bladder cancer ( NMIBC ) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk‐adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC : the American Urological Association ( AUA )/Society of Urologic Oncology ( SUO ), European Association of Urology ( EAU ), National Comprehensive Cancer Network ( NCCN ), and National Institute for Health and Care Excellence ( NICE ) guidelines.